Castleman Disease Treatment

Castleman disease treatment is shaped by disease subtype, clinical severity, organ involvement, and the availability of specialist diagnosis. Care commonly requires coordinated hematology, oncology, immunology, infectious-disease, pathology, and supportive-care expertise. Because the condition is rare and clinically heterogeneous, treatment decisions depend on confirmed diagnosis, exclusion of mimicking disorders, and individualized assessment of inflammatory activity and complications.

The treatment landscape is moving toward more precise disease classification and coordinated longitudinal management. Differentiating unicentric from multicentric disease, and idiopathic multicentric disease from human herpesvirus 8–associated disease, is central to selecting intervention. Advances in pathology, imaging, biomarker interpretation, and consensus-based diagnostic criteria are helping clinicians reduce delays and align therapy with disease biology. Specialist referral pathways and access to experienced centers remain important because symptoms can overlap with infection, autoimmune disease, lymphoma, and other inflammatory syndromes.

Artificial intelligence can assist Castleman disease care by identifying relevant patterns in pathology, imaging, laboratory results, and longitudinal records, while natural-language systems can help organize dispersed clinical evidence and flag potentially overlooked diagnostic criteria. Its greatest near-term value is likely to be workflow support rather than autonomous treatment selection. Rare-disease datasets are small and heterogeneous, making external validation, explainability, privacy protection, and clinician oversight essential. AI tools should complement multidisciplinary judgment and should not replace confirmatory testing or individualized risk assessment.

North America generally benefits from established rare-disease networks, specialist centers, and access to advanced diagnostics, although geographic and insurance-related barriers can affect continuity of care. Europe combines strong academic expertise with variation across national reimbursement, referral, and diagnostic systems. Asia-Pacific includes highly developed specialist environments alongside substantial access differences between urban and rural settings. Latin America may face delays related to specialist availability, pathology capacity, and treatment access. The Middle East shows growing investment in tertiary care but uneven concentration of expertise, while Africa continues to encounter limited rare-disease recognition, diagnostic infrastructure, and specialist coverage. Across all regions, cross-border consultation, standardized referral pathways, and registry development can improve consistency.

Within ASEAN, differences in laboratory capacity, specialist distribution, and reimbursement influence access to diagnosis and treatment. BRICS members span substantial variation in health-system resources, with major academic centers often serving as referral hubs. The European Union benefits from collaborative research and cross-border policy mechanisms, but national implementation remains uneven. G7 systems generally possess strong specialist and research capabilities, while affordability and care coordination can still vary. GCC countries have invested in advanced hospital infrastructure and may concentrate complex-care expertise in leading centers. NATO members represent diverse health systems, yet collaboration, military medical networks, and shared research capabilities can support rare-disease preparedness. These groupings should be interpreted as institutional contexts rather than uniform treatment markets.

Australia can leverage centralized specialist networks and rare-disease programs, while Brazil and Mexico continue to benefit from stronger referral coordination and expanded diagnostic capacity. Canada and the United States have established specialist expertise, but distance, coverage, and care fragmentation may affect access. China and India combine large clinical populations with rapidly developing tertiary-care capabilities, alongside marked regional variation. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom have substantial academic and clinical resources, with differences in reimbursement, referral models, and registry integration. Russia’s care environment reflects variation in specialist access and diagnostic infrastructure. Across these countries, timely pathology review, subtype confirmation, treatment monitoring, and coordinated follow-up remain practical priorities.

Industry leaders should support multidisciplinary referral pathways linking community clinicians with experienced hematology and rare-disease centers. Investment in validated diagnostic workflows, centralized pathology review, interoperable registries, and structured longitudinal data can improve recognition and treatment monitoring. Education should emphasize subtype differentiation, exclusion of mimicking conditions, infection assessment, and management of inflammatory or organ-related complications. Developers and care organizations should generate high-quality real-world evidence while protecting patient privacy, and any AI deployment should include transparent validation, bias monitoring, and clinician accountability. Partnerships with patient organizations can also improve treatment literacy and continuity of care.

This executive summary uses a qualitative evidence-synthesis approach focused on established clinical principles, disease classification, diagnostic practice, treatment coordination, health-system access, and responsible technology adoption. Analysis is organized across the required regional, institutional-group, and country perspectives. Because Castleman disease is rare and heterogeneous, interpretation emphasizes clinically documented patterns and system-level differences rather than unsupported numerical comparisons. Conclusions should be refreshed as guidelines, diagnostic criteria, clinical evidence, regulatory decisions, and access conditions evolve.

Castleman disease treatment is increasingly defined by diagnostic precision, subtype-aware management, and collaboration across specialties. Progress will depend on earlier recognition, reliable access to expert review, consistent monitoring, and stronger evidence generation across diverse care settings. Regional and country differences make adaptable referral and support models essential. Used responsibly, digital tools and artificial intelligence can strengthen these capabilities, but high-quality clinical judgment and patient-centered multidisciplinary care remain the foundation.